Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease - Tabular View

Tracking Information

First Received Date ^ICMJE

August 31, 2006

Last Updated Date

February 26, 2007

Start Date ^ICMJE

May 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00370734 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease

Official Title ^ICMJE

Brief Summary

In active phase of thyroid eye disease some patients have obvious upper lid retraction , and sometimes exposure keratopathy .To date there is not any standard treatment for this situation . We are going to compare the natural course of the upper lid retraction with injection of botulinum toxin A injection to upper lid percutaneously.

Detailed Description

Study Phase

Phase II, Phase III

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study

Condition ^ICMJE

Eye Diseases

Intervention ^ICMJE

Drug: Botulinum toxin A injection

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

February 2007

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

all the patients wiht oper lid retraction in active phase of thyroid ophthalmopathy

Exclusion Criteria:

patients in non active phase

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Babak Babsharif, MD

+98 21 22585952

labbafi@hotmail.com

Location Countries ^ICMJE

Iran, Islamic Republic of

Administrative Information

NCT ID ^ICMJE

NCT00370734

Responsible Party

Study ID Numbers ^ICMJE

8375

Study Sponsor ^ICMJE

Shaheed Beheshti Medical University

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:

Babak Babsharif, MD

Ophthalmic Research Center of Shaheed Beheshti Medical University

Information Provided By

Shaheed Beheshti Medical University

Verification Date

February 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP